http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Adenosine A2A Receptor Antagonists, Volume 170 in the International Review of Neurobiology series highlights new advances in the field, with this new volume presenting interesting chapters on a variety of timely topics, including A2A Adenosine Receptor Agonists, Antagonists, Inverse Agonists and Partial Agonist, Chemistry - agonists, antagonists, partial agonists, inverse agonists, Functional roles of adenosine receptors - biochemistry and neuronal plasticity, A2A and Depression, A2AR and glial function, The adenosine A2A receptor in the basal ganglia: expression in health and disease, heteromerization, functional selectivity and signaling, How and why A2a receptor become to be a therapeutic target in Parkinson's disease therapy, and much more.
Front cover -- Series page -- Title page -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists -- 1 Introduction -- 2 A2AAR agonists -- 3 Positive allosteric enhancers (PAMs) -- 4 A2AAR antagonists and inverse agonists -- 5 Negative allosteric enhancers (NAMs) -- 6 A2AAR partial agonists -- 7 Conclusions -- References -- Chapter Two: Adenosine A2A receptor and glia -- 1 Preface -- 2 A2AR in astrocytes -- 3 Astrocyte A2AR and Alzheimer's disease -- 4 Astrocyte A2AR and PD -- 5 A2AR and microglia
6 Microglial A2A receptor and process retraction -- 7 Microglial A2A receptor and neuroinflammation -- 8 Microglial A2AR and AD -- 9 Microglial adenosine A2AR and PD -- 10 Microglial adenosine A2A receptor and stroke -- 11 Microglial A2AR in other diseases -- 12 Role of other microglial adenosine A1 and A3 receptors -- 13 A2AR and oligodendrocytes -- 14 Perspective -- References -- Chapter Three: The adenosine A2A receptor in the basal ganglia: Expression, heteromerization, functional selectivity and signalling -- 1 Introduction -- 2 Expression of A2AR in the basal ganglia
3 Functional selectivity and signalling of A2AR -- 3.1 A2ARs as monomers -- 3.2 A2ARs as heteromers -- 3.3 A2AR-containing heteromers with relevance in basal ganglia circuits -- 3.4 Multiple mechanisms of action of A2AR antagonists -- 3.5 A2AR mediates the adenosine-dopamine functional interactions in the basal ganglia -- 4 Heteromer expression in neurological diseases affecting the basal ganglia and in alterations of the reward circuits by drugs of abuse -- 5 Concluding remarks -- Conflict of interests -- Author contribution -- Funding -- References
Chapter Four: How and why the adenosine A2A receptor became a target for Parkinson's disease therapy -- How and why the adenosine A2A receptor became a target for Parkinson's disease therapy -- 1 Introduction -- 2 The relevance of the adenosinergic system and the A2A adenosine receptor -- 3 Adenosine A2A receptors and motor function -- 4 Adenosine A2A antagonists and dyskinesia -- 5 Adenosine A2A antagonists and motor function in Parkinson's disease -- 6 Other potential mechanisms of action of A2A adenosine antagonists -- 7 Adenosine antagonists and non-motor symptoms of Parkinson's disease
8 Exploring the future potential of adenosine A2A antagonists in Parkinson's disease -- References -- Chapter Five: Adenosine A2A antagonists and Parkinson's diseaseAdenosine A2A antagonists and Parkinson's disease -- 1 Introduction -- 2 Receptor agonists -- 2.1 Dopamine receptor agonists -- 2.1.1 Ergot dopamine agonists -- 2.1.2 Non-ergot dopamine agonists -- 3 Inverse agonists -- 3.1 Serotonin receptor 2A inverse agonists -- 4 Receptor antagonists -- 4.1 Dopamine receptor antagonists -- 4.2 NMDA receptor antagonists -- 4.3 Acetylcholine receptor antagonists -- 4.4 Adenosine receptor antagonists
Chapter six -- Chapter seven -- Chapter eight -- Chapter nine -- Chapter ten -- Chapter eleven.
International review of neurobiology ; v. 170